Relmada Therapeutics Inc Stock
Relmada Therapeutics Inc Stock price
Key metrics
| Market capitalization | $90.82m |
| Enterprise Value | $7.21m |
| PER (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 1.26 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-98.54m |
| Free Cash Flow (TTM) Free Cash Flow | $-48.19m |
| Cash position | $83.61m |
Is Relmada Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
Relmada Therapeutics Inc Stock Analysis
Analyst Opinions
4 Analysts have issued a Relmada Therapeutics Inc forecast:
Analyst Opinions
4 Analysts have issued a Relmada Therapeutics Inc forecast:
Financial data from Relmada Therapeutics Inc
| Dec '23 |
+/-
%
|
||
| Net Profit | -99 -99 |
37%
37%
|
|
| Depreciation and Amortization | - - |
-
|
|
| Stock Compensation | 44 44 |
1%
1%
|
|
| Operating Cash Flow | -52 -52 |
50%
50%
|
|
| Investments | - - |
-
|
|
| Dividend Paid | - - |
-
|
|
| Free Cash Flow | -52 -52 |
50%
50%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Relmada Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Relmada Therapeutics Inc Stock News
Company Profile
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Sergio Traversa |
| Employees | 20 |
| Founded | 2012 |
| Website | www.relmada.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
